❌

Normal view

Received yesterday — 2 June 2026 ⏭

New Integrated PET Imaging Platform Quickly Identifies Clear Surgical Margins in Osteosarcoma Resection

✇Science Mag
By: SCIENMAG
2 June 2026 at 21:42

A groundbreaking advancement in the imaging and surgical treatment of osteosarcoma promises to revolutionize how this aggressive bone cancer is managed, offering hope for improved outcomes through cutting-edge precision technology. At the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, researchers from Peking University Cancer Hospital and Institute in Beijing will unveil an innovative integrated PET imaging platform capable of rapidly and accurately distinguishing malignant tumor tissue from healthy tissue during surgery. This novel system not only enhances real-time decision-making in the operating room but also enables precise assessment of surgical margins, a critical factor in fully eradicating tumors and minimizing recurrence.

Osteosarcoma, the most common primary malignant bone tumor affecting children and adolescents, represents a formidable clinical challenge. The current therapeutic standard combines aggressive chemotherapy with radical surgical excision. A paramount objective for surgeons is to remove the entire tumor with clear margins, as residual tumor cells within resection boundaries markedly increase the risk of local recurrence and negatively impact patient survival. However, delineating tumor margins intraoperatively with confidence remains difficult, frequently requiring surgeons to make empirical decisions based on visual and tactile feedback—methods insufficient for microscopic precision.

This clinical necessity spurred the development of a sophisticated multi-modal imaging platform engineered to overcome existing limitations. Central to the technology is the targeting of B7-H3, a transmembrane protein highly expressed in over 80% of osteosarcoma tumors. Recognizing this protein’s selective overexpression, researchers successfully synthesized a novel radiotracer, designated ^68Ga-B7H3-BCH, that selectively binds to B7-H3 molecules, enabling highly specific and sensitive detection of osteosarcoma lesions through PET imaging.

Preclinical assessments underscored the superior diagnostic capability of the ^68Ga-B7H3-BCH tracer, demonstrating marked improvements in lesion detection and tumor delineation compared to conventional radiotracers like ^18F-FDG. Encouraged by these findings, the research team architected an integrated imaging pipeline that synergizes ^68Ga-B7H3-BCH PET/CT scanning with a near-infrared (NIR) B7H3 fluorescent probe. This dual-modality approach facilitates comprehensive preoperative tumor staging and equips surgeons with real-time fluorescence visualization during tumor resection procedures.

During the surgical phase, the NIR fluorescent probe illuminates tumor borders with high spatial and temporal resolution, guiding surgeons to excise malignant tissues precisely while preserving as much healthy bone and surrounding structures as possible, which is vital for maintaining limb functionality. Following tumor removal, the platform incorporates a rapid pathological margin verification technique capable of providing conclusive margin status within 30 minutes, dramatically expediting what traditionally is a protracted pathological process and enhancing surgical confidence.

Mouse model studies exhibited robust uptake of the ^68Ga-B7H3-BCH tracer within osteosarcoma lesions and at tumor margins, correlating well with histopathological analysis and validating the tracer’s specificity. The combination of non-invasive, whole-body PET/CT imaging for systemic staging and intraoperative fluorescence for margin delineation embodies a truly personalized, closed-loop diagnostic and therapeutic strategy.

The implications of this integrated platform extend beyond mere imaging enhancements. It introduces a paradigm shift toward precision oncology in osteosarcoma, transitioning from empirical surgery followed by standard systemic chemotherapy to individualized treatment plans shaped by precise molecular and anatomical tumor information. Such tailoring is poised not only to improve local control rates but also to reduce unnecessary removal of healthy tissue, ultimately translating into better functional outcomes and quality of life for patients.

Bo Mei, PhD, the principal investigator spearheading this innovation, emphasized the urgent clinical need: “Orthopedic surgeons need a reliable, rapid method to accurately delineate tumor margins in real-time during osteosarcoma surgeries. Our integrated platform meets this challenge, redefining surgical oncology practices by incorporating molecular targeting and advanced imaging modalities.”

Although still at the investigational stage, early human feasibility studies employing the ^68Ga-B7H3-BCH platform have shown promising results. These pilot data demonstrate the platform’s potential to function effectively in clinical settings, marking a critical step toward regulatory approval and widespread adoption. Future efforts will focus on comprehensive prospective clinical trials to robustly establish safety, efficacy, and workflow integration within orthopedic oncology centers.

The technical innovation rests heavily on multimodal probe development, marrying the quantitative power of PET imaging with the exquisite real-time spatial resolution of fluorescence imaging. This combination overcomes intrinsic limitations of each modality when used in isolation—PET provides metabolic and molecular insights but is limited in spatial resolution and intraoperative applicability, while fluorescence enables visual guidance but lacks systemic diagnostic capability.

The platform’s rapid intraoperative margin assessment, with results available in less than half an hour, is a significant advance that replaces delayed histopathology consultation, allowing surgeons to adjust the extent of resection dynamically and immediately. By integrating molecular targeting, imaging, and pathology, this closed-loop diagnostic and therapeutic construct exemplifies next-generation precision medicine and theranostics.

This innovation also represents a promising template for other solid tumors exhibiting targetable biomarkers, suggesting broad applicability across oncology. The integration of molecularly specific PET tracers with intraoperative fluorescence guidance and rapid pathology verification embodies a comprehensive approach that can be adapted and refined for diverse malignancies beyond osteosarcoma.

As SNMMI 2026 unfolds, this pioneering work will undoubtedly attract attention from the nuclear medicine, surgical oncology, and molecular imaging communities. The researchers’ abstract, detailing the development and validation of the ^68Ga-B7H3-BCH PET/fluorescence multimodal probe and integrated imaging platform, underscores the convergence of technology and translational science, poised to enhance patient care profoundly.

This new frontier in osteosarcoma management showcases how targeted molecular imaging coupled with innovative surgical navigation can dramatically improve diagnostic accuracy, surgical precision, and ultimately patient prognosis. It exemplifies the power of integrating molecular biology, chemistry, imaging technology, and clinical expertise into a cohesive solution designed to address one of the most challenging pediatric cancers.

Subject of Research: Osteosarcoma, molecular imaging, surgical margin assessment, precision oncology
Article Title: An Integrated PET Imaging Platform for Real-Time Surgical Guidance and Accurate Margin Assessment in Osteosarcoma
News Publication Date: 2026 (presented at SNMMI Annual Meeting)
Web References: SNMMI 2026 Annual Meeting Abstract
Image Credits: Courtesy of SNMMI
Keywords: Osteosarcoma, B7-H3, PET Imaging, Molecular Imaging, Near-Infrared Fluorescence, Surgical Navigation, Radiotracer, Precision Medicine, Tumor Margin, Theranostics

Gut Microbiome Reactivates Androgens to Control Motility

✇Science Mag
By: SCIENMAG
2 June 2026 at 21:40

In an unprecedented exploration into the dynamic interplay between microbiota and host physiology, a groundbreaking study has illuminated the pivotal role of microbial enzymes in modulating gut motility through reactivation of host androgens. Published in Nature Neuroscience in 2026, this research uncovers how microbial metabolism intricately directs enteric neuronal circuits, reshaping our understanding of the gut-brain axis with profound implications for human health and disease.

The study embarks from the well-documented influence of androgens—steroid hormones traditionally associated with male traits—on various physiological systems. While systemic androgen effects have been explored, this investigation probes deeper into localized reactivation mechanisms within the gut environment, where microbial communities reside densely. Researchers reveal that resident gut microbes possess enzymatic functions capable of converting androgen precursors back into their active forms, effectively reawakening hormonal signaling within the enteric nervous system.

Employing a sophisticated combination of metabolomic profiling, genetic manipulation, and electrophysiological techniques, the team identified key bacterial taxa responsible for this enzymatic reactivation. Notably, these microbial metabolic activities were found to significantly enhance the bioavailability of active androgens in the gut lumen, directly influencing neuronal excitability and, consequently, gut motility patterns. This discovery bridges a vital gap between microbiome functionality and neuroendocrine regulation that had remained elusive until now.

Central to the findings is the concept that androgen reactivation by microbial enzymes fine-tunes enteric neuronal output, orchestrating peristaltic reflexes and smooth muscle contractions essential for intestinal transit. Through targeted in vivo experiments, the researchers demonstrated that disruption of this microbial androgen metabolism altered gut motility, resulting in either hypo- or hypermotility phenotypes. These effects were reversible upon restoration of the microbial enzymatic activity, suggesting a highly dynamic and plastic system governed by host-microbiome feedback loops.

Beyond the immediate mechanistic insights, this study challenges conventional paradigms by positioning gut microbes as active endocrine modulators rather than passive inhabitants. The realization that microbial metabolism can recalibrate host hormonal circuits highlights novel avenues for therapeutic intervention in gastrointestinal disorders characterized by dysmotility, such as irritable bowel syndrome and chronic constipation. Modulating microbial androgen reactivation could become a precision medicine strategy tailored to restore normal gut function.

Intriguingly, the researchers also unveiled sexually dimorphic responses in the interplay between microbial androgen reactivation and enteric neuron function. Male and female mice exhibited distinct motility patterns contingent upon variations in microbial enzymatic profiles and host androgen sensitivity, underscoring the importance of considering sex as a biological variable in gut-neuroendocrine research. This facet deepens our appreciation of individualized host-microbe interactions shaping health outcomes.

At the molecular level, the study elaborates on how microbial enzymes such as hydroxysteroid dehydrogenases catalyze reversible conversions between inactive androgen conjugates and their active counterparts. These enzymatic reactions take place in close proximity to enteric neurons, facilitating paracrine signaling that modulates neuronal firing rates and neurotransmitter release. This finely tuned mechanism enables the microbiome to exert sophisticated control over gut motility beyond mere metabolite production.

Furthermore, the research integrates advanced imaging modalities to visualize neuronal activity in real-time, correlating enhanced androgen availability with increased calcium fluxes and action potential frequency within enteric ganglia. This real-time functional evidence solidifies the link between microbial metabolic activity and neurophysiological outputs, offering a multi-dimensional perspective of gut regulatory networks. The convergence of metabolic and neuronal data lends robust credibility to the proposed model.

From an evolutionary standpoint, the elucidation of microbial androgen reactivation mechanisms hints at a co-evolved symbiotic relationship where microbes contribute to optimizing host intestinal function. This evolutionary insight expands the framework of mutualism, suggesting that microbiota-derived modulation of hormone signaling constitutes an adaptive advantage for maintaining digestive efficiency. Such findings provide fertile ground for evolutionary biology and microbiome research intersections.

The translational potential of these discoveries is immense. By identifying specific microbial enzyme targets, pharmaceutical development can aim to design modulators or probiotics that enhance or inhibit androgen reactivation within the gut, thereby controlling motility disorders. Moreover, these microbial pathways might influence systemic endocrine functions given the interconnectivity between enteric neurons and central nervous system circuits, opening exciting possibilities for neurogastroenterology.

Intricately, the study also discusses the feedback mechanisms wherein host androgens modulate microbial community composition and metabolic activity, establishing a bidirectional communication loop. This dynamic feedback ensures homeostasis by synchronizing microbial function with host hormonal status, representing an elegant biological system integrating metabolic, neuronal, and microbial domains. Such complexity underscores the need for holistic approaches in future gut-brain axis investigations.

Given the widespread prevalence of gut motility disorders, the identification of microbial androgen reactivation as a key regulatory mechanism invites renewed scrutiny of microbiome-targeted therapies. Dietary interventions, antibiotics, and microbiota transplants could inadvertently perturb these enzymatic activities, altering gut function. Therefore, medical practices may need to incorporate microbiome endocrine considerations to optimize patient outcomes and minimize adverse effects.

In conclusion, this seminal study redefines the microbial contribution to host physiology by unveiling a novel enzymatic process through which gut bacteria reactivate androgens, orchestrating enteric neuronal regulation of motility. This intricate biochemical crosstalk exemplifies the emerging frontier of microbiome-endocrine interactions with vast implications for biology, medicine, and therapeutics. As we unravel these complex dialogues, the prospect of leveraging microbial endocrinology to modulate health becomes an exciting reality.

The transformative insights gained here invite a paradigm shift: the gut microbiome is not merely a metabolic organ but an endocrine entity capable of recalibrating host neurophysiological processes. This revelation paves the way for integrative research endeavors bridging microbiology, endocrinology, neuroscience, and clinical medicine, ultimately advancing personalized healthcare in gastrointestinal and systemic diseases. Such interdisciplinary synergy heralds a new epoch of microbiome-informed biomedical breakthroughs.

As the field advances, further studies will doubtless explore how microbial androgen reactivation interfaces with other hormonal axes and systemic immunity, deepening our comprehension of host-microbiome symbiosis. The interplay between microbial enzymatic activities and host signaling cascades likely extends beyond gut motility, influencing metabolism, mood, and behavior. The future of human health hinges upon decoding these microbial endocrine networks and harnessing their potential.

Subject of Research: Microbial enzymatic reactivation of host androgens and their role in enteric neuronal regulation of gut motility.

Article Title: Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility.

Article References:
Lagomarsino, V.N., Robinson, A., Mitchell, P.E. et al. Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility. Nat Neurosci (2026). https://doi.org/10.1038/s41593-026-02321-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-026-02321-0

Quand la Lune était géante dans le ciel, elle aurait maintenu la Terre en enfer… et préparé la vie

✇Les dernières actualités de Futura
By: Morgane Gillard · Rédactrice
2 June 2026 at 20:03
Il y a 4,5 milliards d’années, la Terre n’avait rien d’un monde habitable : recouverte d’un océan de magma et enveloppée d’une atmosphère étouffante, elle était pourtant déjà le théâtre de processus essentiels à l’émergence de la vie. Une nouvelle étude montre que la jeune Lune, en exerçant...

❌